PTC Therapeutics(PTCT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, total net product and royalty revenue was $263 million, with full-year 2025 total net product and royalty revenue reaching $831 million, exceeding guidance of $750 million-$800 million [5][17] - Non-GAAP R&D and SG&A operating expenses for 2025 were $728 million, below the guidance of $730 million-$760 million [6] - Cash, cash equivalents, and marketable securities totaled $1.95 billion as of December 31, 2025, compared to $1.14 billion as of December 31, 2024 [21] Business Line Data and Key Metrics Changes - Sephience generated $92 million in revenue in Q4 2025 and $111 million since its launch in 2025 [5][12] - The DMD franchise revenue for Q4 2025 was $66 million, with Translarna contributing $39 million and Emflaza $27 million [17] - Evrysdi royalty revenue for full-year 2025 was $244 million [18] Market Data and Key Metrics Changes - Sephience has seen broad uptake across all patient segments, with 946 patients on commercial therapy worldwide by the end of 2025 [13] - In the U.S., 80% of PKU Centers of Excellence have written prescriptions for Sephience [13] - The company expects to have patients on commercial drug in 20-30 countries by the end of 2026, with Japan's launch anticipated soon [8][15] Company Strategy and Development Direction - The main focus for 2026 will be to continue the momentum of the Sephience launch, with expectations for revenue growth through increased market penetration and geographic expansion [7][8] - The company aims to reach cash flow break-even in 2026, a significant milestone [7][20] - The R&D pipeline includes advancing programs from RNA splicing and ferroptosis inflammation platforms, with several early-stage programs expected to progress [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Sephience's potential, citing a multi-billion dollar global revenue opportunity due to its differentiated profile and unmet need in the PKU market [8][15] - The management highlighted the importance of social media in driving awareness and engagement among patients, particularly those previously lost to follow-up [30][31] - The company remains optimistic about the future, with a robust commercial engine and innovative R&D programs [10] Other Important Information - The company sold the remainder of its Evrysdi royalty for $240 million in December 2025, which will not generate cash proceeds for PTC but maintains the right to receive a $150 million milestone from Roche [19][20] - The company is preparing for pricing and reimbursement negotiations in key markets, including Japan and Brazil, with expectations for meaningful revenue contributions from these regions [15][70] Q&A Session Summary Question: What is included in the guidance for Sephience sales this year? - The revenue guidance of $700 million-$800 million is primarily from Sephience, with contributions expected from mature products as well [22][23] Question: How are lost to follow-up patients becoming aware of Sephience? - Engagement through social media has played a significant role in raising awareness among patients who were previously lost to follow-up [30][31] Question: Can you provide details on the additional study requested by the FDA for vatiquinone? - The FDA suggested an open-label or single-arm study with a natural history comparator group, and the company plans to meet with the FDA to finalize the protocol [39][40] Question: What are the expectations for Sephience's discontinuation rate? - The company is seeing very low discontinuation rates, with high prescription renewal rates, which is encouraging for future growth [46][47] Question: How will pricing and reimbursement dynamics evolve in Europe? - The company is in the process of negotiating pricing and reimbursement in Germany, with expectations for a favorable outcome based on strong clinical data [52][53]